Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.


TSX:MDNA - Post by User

Comment by Pandoraon May 05, 2021 12:00pm
171 Views
Post# 33132405

RE:Breaking down badly

RE:Breaking down badly
juniorbullalive wrote: Is there a risk of an FDA rejection ? 


May of 2020 was a good month for MDNA. The share price ran up to the 52 week high of $7.25 by the end of May. Since then it has been primarily a $5 to $5.50 stock price and over the past month has been totally beaten down to the low $4 range -- $4.13 today.

Not sure why it is so depressed but some good news would probably help and that would have to be something other than attending another zoom conference. I would estimate that about 12 of the last 16 news items over the past 6 months have been re attending conferences.

A good old fashioned news release regarding achieving some new objective or standard is what is needed.
<< Previous
Bullboard Posts
Next >>